ウルソデオキシコール酸 (Synonyms: Ursodeoxycholic acid; Ursodeoxycholate; Ursodiol; UDCA)

Name: Ursodeoxycholic acid
Brand: MedChemExpress
SKU: HY-13771
Rating: 5.0 (26 reviews)

製品番号: HY-13771 純度: 99.94%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 128-13-2

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 33	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 33	在庫あり	Estimated Time of Arrival: December 31
Solid
1 g	$30	在庫あり	Estimated Time of Arrival: December 31
5 g	$50	在庫あり	Estimated Time of Arrival: December 31
10 g		お問い合わせ
50 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 26 publication(s) in Google Scholar

Other Forms of Ursodeoxycholic acid:

顧客検証

RT-PCR

Others

Histological Imaging/Staining

: Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 16;16(1):7638. [Abstract]; Mice were gavaged with B. breve or R. gnavus and then treated with BSH inhibitor riboflavin or 7β-HSDH inhibitor Ursodeoxycholic acid (UDCA) (50 mg/kg, p.o.) H&E staining showed normal, dysplastic mucosae and carcinoma in the colon tissues.

: Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 27:e15370. [Abstract]; RT‐PCR analysis showed that Ursodeoxycholic acid (UDCA) (20 μM. 24 h) supplementation significantly increased the mRNA levels of critical markers of ISCs.

: Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb 3:e2411719. [Abstract]; The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.

: Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 27:e15370. [Abstract]; Protein immunoblotting analysis showed that Ursodeoxycholic acid (UDCA) (20 μM, 24 h) supplementation reduced the protein expression of the bile acids receptor FXR.

: Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 27:e15370. [Abstract]; Ursodeoxycholic acid (UDCA) (20 μM, 7 days) treatment increased the protein levels of active β‐catenin in organoid cultures by immunofluorescence images.

: Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2024 Feb 14;32(2):191-208.e9. [Abstract]; H&E-stained demonstrated Ursodeoxycholic acid (UDCA) (50 mg/kg/day, gavage, 2 weeks) and 7-keto-LCA protected against aspirin-induced intestinal epithelial damage.

: Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 2;14(1):2523. [Abstract]; Ursodeoxycholic acid (UDCA) (0.1 mM, 6 h) blocked OA-decreased PREP activity and -increased BK content.

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Human Endogenous Metabolite Microbial Metabolite

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target^[3]^[4]

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 200 μM Compound: UDCA	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
CHO	EC₅₀	36.4 μM Compound: 9, UDCA	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
COS-1	EC₅₀	> 50 μM Compound: 9, UDCA	Agonist activity at human FXR expressed in COS1 cells by luciferase assay Agonist activity at human FXR expressed in COS1 cells by luciferase assay	[PMID: 18307294]
GBM	IC₅₀	> 50 μM Compound: 1b, UDCA, ursodeoxycholic acid	Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
HCT-116	IC₅₀	> 200 μM Compound: UDCA	Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
HCT-116	IC₅₀	> 50 μM Compound: 1b, UDCA, ursodeoxycholic acid	Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
HEK-293T	EC₅₀	> 150 μM Compound: UDCA	Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HEK-293T	IC₅₀	> 50 μM Compound: UDCA	Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HEK293	EC₅₀	2.39 μM Compound: 3, UDCA	Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay	[PMID: 25735208]
HET-1A	CC₅₀	1313 μM Compound: 7, UDCA	Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 20713311]
HT-29	IC₅₀	> 200 μM Compound: UDCA	Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
HeLa	IC₅₀	3.6 μM Compound: Ursodeoxycholate	TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells	[PMID: 10565843]
Huh-7	IC₅₀	> 200 μM Compound: UDCA	Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
KMS-11	IC₅₀	> 50 μM Compound: 1b, UDCA, ursodeoxycholic acid	Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
LoVo	IC₅₀	> 200 μM Compound: UDCA	Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
MGC-803	IC₅₀	> 200 μM Compound: UDCA	Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
RKO	IC₅₀	> 200 μM Compound: UDCA	Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SK-HEP1	IC₅₀	> 200 μM Compound: UDCA	Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SW480	IC₅₀	> 200 μM Compound: UDCA	Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]

体外実験

Ursodeoxycholic acid (10 μM; 24 h) reduces ACE2 and SHP levels in primary airway and intestinal organoids, and reduces SARS-CoV-2 infection in multiple cell types via FXR-mediated ACE2 regulation^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Ursodeoxycholic acid (50, 150, and 450 mg/kg; p.o.; daily for 21 days) results in weight loss in C57BL/6J wildtype mice^[1].
Ursodeoxycholic acid (1% w/w or 416 mg/kg; oral; 7 days) reduces ACE2 expression in mice and hamsters^[4].
Ursodeoxycholic acid (416 mg/kg; oral; 7 days) reduces SARS-CoV-2 infection in hamsters^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5 week old C57BL/6J WT mice (male and female)^[1]
Dosage:	50, 150, and 450 mg/kg dissolved in corn oil
Administration:	Oral gavage; daily for 21 days
Result:	Mice in the 50 and 450 mg/kg groups sustained significant weight loss within a week. At 50 mg/kg, this weight loss persisted over the course of the experiment. At 450 mg/kg, initially weight loss was noted during the first and third week of ursodiol administration. At 150 mg/kg, it did not have significantly different weights compared to the untreated mice.

Animal Model:	FVB/N mice and Syrian Golden Hamsters^[4]
Dosage:	1% w/w for mice, 416 mg/kg for hamsters
Administration:	In chow or oral gavage, 7 days
Result:	Reduced ACE2 expression.

Animal Model:	Syrian Golden Hamsters, SARS-CoV-2 infection model^[4]
Dosage:	416 mg/kg
Administration:	Oral gavage, 7 days
Result:	Prevented transmission of SARS-CoV-2 in n=6 out of 9 sentinel animals (33% infected vs. 67% uninfected).

臨床実験

分子量

392.57

分子式

C₂₄H₄₀O₄

CAS 番号

128-13-2

Appearance

Solid

Color

White to off-white

SMILES

C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C

Structure Classification

Steroids

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (254.73 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5473 mL	12.7366 mL	25.4732 mL
5 mM	0.5095 mL	2.5473 mL	5.0946 mL
10 mM	0.2547 mL	1.2737 mL	2.5473 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.94%

Select Batch:

データシート (280 KB) SDS (396 KB)

COA (250 KB) HNMR (270 KB) RP-HPLC (238 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Winston JA, et al. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021;16(2):e0246161. Published 2021 Feb 18. [Content Brief]

[2]. Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46(4):1131-7. [Content Brief]

[3]. Kumar D, et al. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16(1):3-14. [Content Brief]

[4]. Brevini T, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022 Dec 5. [Content Brief]

[5]. Biao Nie, et al. Specific Bile Acids Inhibit Hepatic Fatty Acid Uptake in Mice. Hepatology. 2012 Oct;56(4):1300-10. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5473 mL	12.7366 mL	25.4732 mL	63.6829 mL
	5 mM	0.5095 mL	2.5473 mL	5.0946 mL	12.7366 mL
	10 mM	0.2547 mL	1.2737 mL	2.5473 mL	6.3683 mL
	15 mM	0.1698 mL	0.8491 mL	1.6982 mL	4.2455 mL
	20 mM	0.1274 mL	0.6368 mL	1.2737 mL	3.1841 mL
	25 mM	0.1019 mL	0.5095 mL	1.0189 mL	2.5473 mL
	30 mM	0.0849 mL	0.4246 mL	0.8491 mL	2.1228 mL
	40 mM	0.0637 mL	0.3184 mL	0.6368 mL	1.5921 mL
	50 mM	0.0509 mL	0.2547 mL	0.5095 mL	1.2737 mL
	60 mM	0.0425 mL	0.2123 mL	0.4246 mL	1.0614 mL
	80 mM	0.0318 mL	0.1592 mL	0.3184 mL	0.7960 mL
	100 mM	0.0255 mL	0.1274 mL	0.2547 mL	0.6368 mL

Ursodeoxycholic acid Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

ウルソデオキシコール酸 (Synonyms: Ursodeoxycholic acid; Ursodeoxycholate; Ursodiol; UDCA)

カスタマーレビュー

Other Forms of Ursodeoxycholic acid:

顧客検証

おすすめ

•関連小分子:

•関連タンパク質:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ursodeoxycholic acid Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

ウルソデオキシコール酸 (Synonyms: Ursodeoxycholic acid; Ursodeoxycholate; Ursodiol; UDCA)

カスタマーレビュー

Other Forms of Ursodeoxycholic acid:

ウルソデオキシコール酸 関連抗体

顧客検証

おすすめ

•関連小分子:

•関連タンパク質:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

ウルソデオキシコール酸 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ursodeoxycholic acid Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report

ウルソデオキシコール酸関連抗体

ウルソデオキシコール酸関連抗体